Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death
worldwide. In the past decade, there have been improvements in non-drug therapies and …

Hepatocellular carcinoma (HCC) is the typical inflammation-induced neoplasia. It often
prospers where a chronic liver disease persists, thus leading a strong rationale for immune …

Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable
hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and …

Introduction: In the REFLECT trial, lenvatinib was found to be noninferior compared to
sorafenib in terms of overall survival. Here, we analyze the effects of lenvatinib in the real-life …

Abstract Background Advanced Hepatocarcinoma (HCC) is an important health problem
worldwide. Recently, the REFLECT trial demonstrated the non‐inferiority of Lenvatinib …

Objectives To compare the safety and efficacy of lenvatinib (LEN) combined with
camrelizumab plus transcatheter arterial chemoembolization (TACE-LEN-C) and TACE …

BACKGROUND Lenvatinib has become an indispensable part of treatment regimens for
patients with advanced hepatocellular carcinoma (aHCC). Several recent real-world studies …

Simple Summary As the most common primary liver cancer, HCC is a tricky cancer resistant
to systemic therapies. The fibroblast growth factor family and its receptors are gaining more …

Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy
has been explored in this disease in order to improve survival outcomes. Nowadays …

Background Lenvatinib and atezolizumab plus bevacizumab (A+ B) have been used for
unresectable hepatocellular carcinoma (HCC) as first‐line therapy. Real‐world studies …